---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-061473"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:59:57.284260+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Neumora reports Q4 2023 net loss of $108.7M; cash $463.8M into 2026

## Summary
- Net loss Q4 2023: $108.7M vs $28.1M in Q4 2022; full year net loss $235.9M vs $130.9M.
- Cash, cash equivalents and marketable securities $463.8M as of Dec 31, 2023; expected to fund operations into 2026.
- R&D expenses Q4 2023: $38.9M, up from $23.5M, driven by navacaprant Phase 3 startup and IPR&D costs.
- Topline Phase 3 KOASTAL-1 data for navacaprant in MDD expected H2 2024; KOASTAL-2/3 data in H1 2025.
- Phase 1 data for NMRA-266 (M4 PAM) in healthy adults expected mid-2024; Phase 1b in schizophrenia planned H2 2024.

## SEC filing metadata
- accession: 0001193125-24-061473
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/0001193125-24-061473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/d803910d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-061473
- JSON: https://secwatch.observer/filing/0001193125-24-061473.json
- Plain text: https://secwatch.observer/filing/0001193125-24-061473.txt

## Key facts
- Earnings Releases
  Neumora Therapeutics, Inc. reported financial results for fiscal year ended December 31, 2023.
  - Period: fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 7, 2024, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/0001193125-24-061473-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.